Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment
ADPKD is characterized by progressive cyst formation and enlargement leading to renal failure. Tolvaptan is currently the only FDA-approved treatment for ADPKD; however, it can cause serious adverse effects including hepatotoxicity. There remains an unmet clinical need for effective and safe treatments for ADPKD. The extracellular Ca2+-sensing receptor (CaSR) is a regulator of epithelial ion transport. FDA-approved CaSR activator cinacalcet can reduce cAMP-induced Cl − and fluid secretion in various epithelial cells by activating phosphodiesterases (PDE) that hydrolyze cAMP. (Source: Translational Research)
Source: Translational Research - October 28, 2023 Category: Research Authors: Pattareeya Yottasan, Tifany Chu, Parth D. Chhetri, Onur Cil Source Type: research
Treatment of hypokalemia with amiloride unmasked hypercalcemia and hyperparathyroidism: A case report
Clin Nephrol. 2023 Oct 23. doi: 10.5414/CN111231. Online ahead of print.ABSTRACTColonic pseudo-obstruction, also called Ogilvie's syndrome, occurs due to impaired intestinal propulsion, and may be caused by electrolyte imbalances such as hypokalemia and some endocrine disorders such as hyperparathyroidism. Secretory diarrhea due to intestinal pseudo-obstruction can cause hypokalemia. Diuretics such as amiloride can be used to treat hypokalemia, however in this case, treatment with amiloride induced hypercalcemia and unmasked hyperparathyroidism. A 73-year-old female with a history of hypertension and parathyroid adenoma pr...
Source: Clinical Nephrology - October 23, 2023 Category: Urology & Nephrology Authors: Alexa E Golbus Natalie Freidin Source Type: research
Treatment of hypokalemia with amiloride unmasked hypercalcemia and hyperparathyroidism: A case report
Clin Nephrol. 2023 Oct 23. doi: 10.5414/CN111231. Online ahead of print.ABSTRACTColonic pseudo-obstruction, also called Ogilvie's syndrome, occurs due to impaired intestinal propulsion, and may be caused by electrolyte imbalances such as hypokalemia and some endocrine disorders such as hyperparathyroidism. Secretory diarrhea due to intestinal pseudo-obstruction can cause hypokalemia. Diuretics such as amiloride can be used to treat hypokalemia, however in this case, treatment with amiloride induced hypercalcemia and unmasked hyperparathyroidism. A 73-year-old female with a history of hypertension and parathyroid adenoma pr...
Source: Clinical Nephrology - October 23, 2023 Category: Urology & Nephrology Authors: Alexa E Golbus Natalie Freidin Source Type: research
Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature
CONCLUSIONS: FHH can be seen in heterozygous as well as homozygous CASR gene mutations. Different clinical findings may occur in different individuals from the same family. Cinacalcet therapy can be used successfully in the treatment of individuals with FHH.PMID:37853976 | DOI:10.24953/turkjped.2022.1040 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Serkan Bilge Koca Source Type: research
Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature
CONCLUSIONS: FHH can be seen in heterozygous as well as homozygous CASR gene mutations. Different clinical findings may occur in different individuals from the same family. Cinacalcet therapy can be used successfully in the treatment of individuals with FHH.PMID:37853976 | DOI:10.24953/turkjped.2022.1040 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Serkan Bilge Koca Source Type: research
Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature
CONCLUSIONS: FHH can be seen in heterozygous as well as homozygous CASR gene mutations. Different clinical findings may occur in different individuals from the same family. Cinacalcet therapy can be used successfully in the treatment of individuals with FHH.PMID:37853976 | DOI:10.24953/turkjped.2022.1040 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Serkan Bilge Koca Source Type: research
Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature
CONCLUSIONS: FHH can be seen in heterozygous as well as homozygous CASR gene mutations. Different clinical findings may occur in different individuals from the same family. Cinacalcet therapy can be used successfully in the treatment of individuals with FHH.PMID:37853976 | DOI:10.24953/turkjped.2022.1040 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Serkan Bilge Koca Source Type: research
Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature
CONCLUSIONS: FHH can be seen in heterozygous as well as homozygous CASR gene mutations. Different clinical findings may occur in different individuals from the same family. Cinacalcet therapy can be used successfully in the treatment of individuals with FHH.PMID:37853976 | DOI:10.24953/turkjped.2022.1040 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Serkan Bilge Koca Source Type: research
Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature
CONCLUSIONS: FHH can be seen in heterozygous as well as homozygous CASR gene mutations. Different clinical findings may occur in different individuals from the same family. Cinacalcet therapy can be used successfully in the treatment of individuals with FHH.PMID:37853976 | DOI:10.24953/turkjped.2022.1040 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Serkan Bilge Koca Source Type: research
Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature
CONCLUSIONS: FHH can be seen in heterozygous as well as homozygous CASR gene mutations. Different clinical findings may occur in different individuals from the same family. Cinacalcet therapy can be used successfully in the treatment of individuals with FHH.PMID:37853976 | DOI:10.24953/turkjped.2022.1040 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Serkan Bilge Koca Source Type: research
Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature
CONCLUSIONS: FHH can be seen in heterozygous as well as homozygous CASR gene mutations. Different clinical findings may occur in different individuals from the same family. Cinacalcet therapy can be used successfully in the treatment of individuals with FHH.PMID:37853976 | DOI:10.24953/turkjped.2022.1040 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Serkan Bilge Koca Source Type: research
Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature
CONCLUSIONS: FHH can be seen in heterozygous as well as homozygous CASR gene mutations. Different clinical findings may occur in different individuals from the same family. Cinacalcet therapy can be used successfully in the treatment of individuals with FHH.PMID:37853976 | DOI:10.24953/turkjped.2022.1040 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Serkan Bilge Koca Source Type: research
Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature
CONCLUSIONS: FHH can be seen in heterozygous as well as homozygous CASR gene mutations. Different clinical findings may occur in different individuals from the same family. Cinacalcet therapy can be used successfully in the treatment of individuals with FHH.PMID:37853976 | DOI:10.24953/turkjped.2022.1040 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Serkan Bilge Koca Source Type: research
Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature
CONCLUSIONS: FHH can be seen in heterozygous as well as homozygous CASR gene mutations. Different clinical findings may occur in different individuals from the same family. Cinacalcet therapy can be used successfully in the treatment of individuals with FHH.PMID:37853976 | DOI:10.24953/turkjped.2022.1040 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Serkan Bilge Koca Source Type: research
Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature
CONCLUSIONS: FHH can be seen in heterozygous as well as homozygous CASR gene mutations. Different clinical findings may occur in different individuals from the same family. Cinacalcet therapy can be used successfully in the treatment of individuals with FHH.PMID:37853976 | DOI:10.24953/turkjped.2022.1040 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Serkan Bilge Koca Source Type: research
